The real-world study of Qian Lie Shu Tong Jiao Nang combined with finasteride tablets in the treatment of benign prostatic hyperplasia | [Pakistan Journal of Pharmaceutical Sciences • 2024]

Author(s):

1. Guangjing Tao: Department of Urology, Ankang Central Hospital,Ankang, Shaanxi,China

2. Xiao Wang: Department of Urology, Ankang Central Hospital,Ankang, Shaanxi,China

Abstract:

With the rapid development of traditional Chinese medicine, the combination of Chinese and Western medicine for treating Benign Prostatic Hyperplasia (BPH) has been gradually promoted in clinical medical practice in China. Both Qian Lie Shu Tong Jiao Nang and Finasteride tablets are effective in treating BPH. However, there is a lack of reports on their combined use, so their efficacy and safety still need to be verified. This study explored the clinical effectiveness and safety of Qian Lie Shu Tong Jiao Nang combined with Finasteride tablets for BPH based on real-world data. Results showed that this combination significantly improved the total treatment efficiency (P<0.05) and reduced the International Prostate Symptom Score (IPSS), Chronic Prostatitis Symptom Index (NIH-CPSI), residual urine volume (RUV), tumor necrosis factor (TNF-a) and serum estradiol (E2) levels (all P<0.05). Prostate volume (PV) was notably decreased, while interleukin-10 (IL-10), serum testosterone (T) and maximum urinary flow rate (Qmax) were significantly increased (all P<0.05). The incidence of adverse reactions did not increase with the combination treatment. These observations suggest that the combined use of Qian Lie Shu Tong Jiao Nang and Finasteride tablets may more effectively alleviate BPH symptoms, improve urination functions and have a high safety profile.

Page(s): 1591-1597

DOI: 10.36721/PJPS.2024.37.6.REG.1591-1597.1

Published: Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 37, Issue: 6, Year: 2024

Keywords:

Benign prostatic hyperplasia , finasteride tablets , Qian Lie Shu Tong Jiao Nang , realworld study

References:

[1] Andrade C .2023 .Real world studies: What they are and what they are not. Indian J. Psychol. Med, 45(5) : 537-538.

[2] Choi EP,Chin WY,Lam CL,Wan EY .2015 .The responsiveness of the international prostate symptom score, incontinence impact questionnaire-7 and depression, anxiety and stress scale-21 in patients with lower urinary tract symptoms. J. Adv. Nurs., 71(8) : 1857-1870.

[3] Choi JB,Min SK .2021 .Complicated urinary tract infection in patients with benign prostatic hyperplasia. J. Infect. Chemother., 27(9) : 1284-1287.

[4] De Nunzio C,Salonia A,Gacci M,Ficarra V .2020 .Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol., 38(11) : 2771-2779.

[5] Devlin CM,Simms MS,Maitland NJ .2021 .Benign prostatic hyperplasia - what do we know? BJU Int. , 127(4) : 389-399.

[6] Hata J,Harigane Y,Matsuoka K,Akaihata H,Yaginuma K,Meguro S,Hoshi S,Sato Y,Ogawa S,Uemura M,Kojima Y .2023 .Mechanism of androgenindependent stromal proliferation in benign prostatic hyperplasia. Int. J. Mol. Sci, 24(14) : 11634.

[7] Inamura S and Terada N .2024 .Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int. J. Urol., 31(9) : 968-974.

[8] Joseph DB,Henry GH,Malewska A,Reese JC,Mauck RJ,Gahan JC,Hutchinson RC,Mohler JL,Roehrborn CG,Strand DW .2022 .5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. J. Pathol., 256(4) : 427-441.

[9] Litwin MS .2002 .A review of the development and validation of the national institutes of health chronic prostatitis symptom index. Urology, 60(6 Suppl)) : 14-8.

[10] Ledda A,Belcaro G,Dugall M,Luzzi R,Scoccianti M,Togni S,Appendino G,Ciammaichella G .2012 .Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: A pilot, product evaluation registry study. Panminerva Med, 54(1 Suppl 4) : 17-22.

[11] Liu C,Jiang TT,Zhang C,Gao HL,Wang SY,Zhang MP,Wang ZH,Zhang HX,Zhu WT .2019 .Efficacy, safety and cost of Qianlieshutong Capsules in the treatment of chronic prostatitis. Zhonghua Nan Ke Xue., 25(5) : 444-450.

[12] Liu SJ,Wang F,Gao QH,Zhang JW,Yan B,Liu Y,Guo BD Y .2019 .Effect and safety of the Chinese medicine Qianlieshutong Capsules in the treatment of benign prostatic hyperplasia: A meta-analysis. Zhonghua Nan Ke Xue., 25(11) : 1021-1030.

[13] Li H,Hung A,Li M,Lu L,Yang AWH .2021 .Phytochemistry, pharmacodynamics, and pharmacokinetics of a classic Chinese herbal formula Danggui Beimu Kushen Wan: A review. Phytother Res., 35(7) : 3673-3689.

[14] Lerner LB,McVary KT,Barry MJ,Bixler BR,Dahm P,Das AK,Gandhi MC,Kaplan SA,Kohler TS,Martin L,Parsons JK,Roehrborn CG,Stoffel JT,Welliver C,Wilt TJ C .2021 .Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J. Urol., 206(4) : 806-817.

[15] Li Z,HU S and Li Y .2023 .Effect Observation of Qianlie Shutong capsules combined with finasteride tablets in the treatment of benign prostatic hyperplasia. Chin. J. Drug Abuse Prev. Treat., 29(11) : 2030-2034.

[16] Liedtke V,Stöckle M,Junker K,Roggenbuck D K .2024 .Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence? Autoimmun Rev. , 23(3) : 103511.

[17] Li Z,Hu SW,Li Y .2023 .Effect of Qianlie Shutong capsule combined with tamsulosin hydrochloride capsule on the level of inflammatory factors in patients after TURP. Chin. J. Drug Abuse Prev. Treat., 29(11) : 2030-2034.

[18] Lee GH,Lee HY,Zhao L,Rashid MMU,Kim MK,Jeong YB,Chae HJ,Shin YS .2024 .The role of reactive oxygen species, inflammation and endoplasmic reticulum stress response in the finasteride protective effect against benign prostate hyperplasia. World J. Mens Health, 42(3) : 600-609.

[19] Naiyila X,Li J,Huang Y,Chen B,Zhu M,Li J,Chen Z,Yang L,Ai J,Wei Q,Liu L,Cao D L .1821 .A novel insight into the immune-related interaction of inflammatory cytokines in benign prostatic hyperplasia. J. Clin. Med, 12(5) : .

[20] Plochocki A,King B .2022 .Medical treatment of benign prostatic hyperplasia. Urol. Clin. North Am., 49(2) : 231-238.

[21] Qiao J,Gan Y,Gong Y,Song Q,Zhang B,Li B,Ru F,Li Y,He Y Y .2021 .Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: A single center, randomized control study. Transl Androl Urol., 10(8) : 3432-3439.

[22] Sandhu JS,Bixler BR,Dahm P,Goueli R,Kirkby E,Stoffel JT,Wilt TJ .2024 .Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. , 211(1) : 11-19.

[23] Tsunemori H and Sugimoto M .2021 .Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. Int J Urol., 28(11) : 1086-1092.

[24] Wang N and Li Q .2023 .Simultaneous extraction and analysis of seven major saikosaponins from Bupleuri radix and the exploration of antioxidant activity and its mechanism. Molecules, 28(15) : 5872.

[25] Yin J,Wu M,Wang J,Lu J,Chen Y,Jiang X Y .2022 .Effect of Qianlietongyu capsule combined with tamsulosin hydrochloride in the treatment of prostatitis complicated with premature ejaculation. Indian J. Pharm. Sci., 84 : 108.

[26] Zhang Y,Ma H,Nan T,Li Y,Zheng W,Zhou Z,Gong X .2021 .Comparative efficacy of oral chinese patent medicine for chronic prostatitis/chronic pelvic pain syndrome with sexual dysfunction: A Bayesian network meta-analysis of randomized controlled trials. Front Pharmacol, 12 : 649470.

[27] Zhang ZJ .2021 .Effect of Qianlie Shutong capsule combined with tamsulosin hydrochloride capsule on the level of inflammatory factors in patients after TURP. Chin. J. Surg. Integr. Tradit. West Med, 27(3) : 447-450.

[28] Zhang T,Xun YQ,Liu HL,Ji X,Du X,Zhang F,You W,Fu YB,Sun JQ .2023 .Observation on clinical effect of fire needling for mild to moderate benign prostatic hyperplasia with kidney yang deficiency. Zhongguo Zhen Jiu., 43(1) : 45-50.

[29] Zheng RR,Ouyang QX,Liu ZY,Li LN,Yang L,Wang ZT .2024 .Natural 5α-reductase inhibitors in treatment of benign prostatic hyperplasia. Zhongguo Zhong Yao Za Zhi., 49(4) : 858-867.

Citations

Downloads

Views